|
About Us |
Technology |
Markets |
News |
Contact Us |
Newsroom |
Archives: |
|
|
|
|
|
To receive our press releases and other announcements by e-mail, please send us a request at |
|
November 2005 |
Affinergy, Inc. |
Boston Scientific to Collaborate with Affinergy on Novel Cardiovascular Stent Coatings Affinergy to work with Boston Scientific exclusively in the field of cardiovascular stents. -- more... |
|
July 2005 |
Affinergy, Inc. |
Affinergy Awarded SBIR Grant to Find Growth Factor Mimetics New proprietary compounds to be mined from Affinergy's proprietary libraries -- more... |
|
June 2005 |
Affinergy, Inc. |
Affinergy Awarded Collaborative Funding Grant to Accelerate Research Programs NC Biotechnology Center and Kenan Institute for Engineering, Technology, & Science to sponsor a Kenan Institute/NC Biotechnology Center Fellow -- more... |
|
May 2005 |
Affinergy, Inc. |
Affinergy Adds Proven Healthcare Executive to Leadership Team Greg Mossinghoff to join Affinergy to accelerate product programs and partnering transactions -- more... |
|
April 2005 |
Affinergy, Inc. |
Affinergy Receives SBIR Grant to Accelerate Research on Medical Device Materials Affinergy's "site-specific biological delivery system" will be developed and validated for improved cell attachment to metal implant surfaces -- more... |
|
March 2005 |
Affinergy, Inc. |
Affinergy Awarded Technology Innovation of the Year by Frost & Sullivan Affinergy's site-specific biological delivery system called "breakthrough" with the "potential to become an industry standard." -- more... |
|
March 2005 |
Affinergy, Inc. |
Affinergy Selected to Present at CED Venture Capital Conference Affinergy's "site-specific biological delivery system" to be featured on main stage of prestigious investor conference at Pinehurst. -- more... |
|
January 2005 |
Affinergy, Inc. |
Affinergy Selected to Present at Convergence: The Drug/Device Summit Affinergy's site-specific biological delivery system will be showcased to corporate partners, prospective investors, and industry thought leaders. -- more... |